STOCK TITAN

Galectin Therapeutics Inc - GALT STOCK NEWS

Welcome to our dedicated news page for Galectin Therapeutics (Ticker: GALT), a resource for investors and traders seeking the latest updates and insights on Galectin Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Galectin Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Galectin Therapeutics's position in the market.

Rhea-AI Summary
Galectin Therapeutics, Inc. (GALT) reported financial results for 2023, highlighting progress in their MASH cirrhosis program and the NAVIGATE Phase 2b/3 trial for belapectin. The company secured additional funding, extended cash runway through March 2025, and appointed new board members. The FDA approval of resmetirom for MASH patients with liver fibrosis was noted. The upcoming interim analysis of the NAVIGATE study in Q4 2024 is eagerly anticipated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Summary
Galectin Therapeutics, Inc. appoints Dr. Khurram Jamil as Vice President, Clinical Development. Dr. Jamil brings extensive experience in clinical development, hepatology, and liver cirrhosis. Galectin's Phase 2b/3 NAVIGATE trial of belapectin in NASH cirrhosis is progressing, with interim results expected in Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
management clinical trial
-
Rhea-AI Summary
Galectin Therapeutics, Inc. (NASDAQ: GALT) Reports Financial Results and Business Update, Including Positive Safety Profile of Belapectin and Significant Board Support
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
earnings
Rhea-AI Summary
Galectin Therapeutics Inc. (NASDAQ:GALT) will share five scientific presentations at The Liver Meeting™ 2023, hosted by the American Association for the Study of Liver Diseases (AASLD). The presentations will cover topics such as the pharmacokinetics and safety of belapectin in patients with hepatic insufficiency, the lack of impact of belapectin on cardiac repolarization, and the clinical significance of serum galectin-3 levels in patients with advanced liver disease. The company will also discuss the impact of obesity and muscle wasting on renal function in patients with portal hypertension and NASH cirrhosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
-
Rhea-AI Summary
Galectin Therapeutics Inc. will be participating in the H.C. Wainwright 7th Annual NASH Investor Conference. They will deliver a corporate presentation on October 24, 2023. Belapectin, their complex carbohydrate drug, has shown promising results in reversing liver fibrosis and preventing the development of esophageal varices in NASH cirrhosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
conferences
-
Rhea-AI Summary
Galectin Therapeutics nominates Dr. Benjamin S. Carson, Sr. to serve on the board of directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
management
Rhea-AI Summary
Galectin Therapeutics reports positive outcome of DSMB meeting for NAVIGATE study of belapectin in patients with NASH liver cirrhosis. Study can continue as designed without modifications. Interim topline data from Phase 2b expected in Q4 2024. Belapectin offers beneficial risk-benefit profile for cirrhotic patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
clinical trial
-
Rhea-AI Summary
Galectin Therapeutics will present an update on its belapectin liver cirrhosis program at the Discovery on Target meeting. Belapectin is a galectin-3 inhibitor that can inhibit galectin-3 at its site of production. The presentation will highlight the opportunity the belapectin program offers for patients affected by liver cirrhosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
conferences
-
Rhea-AI Summary
Galectin Therapeutics to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
conferences
Rhea-AI Summary
Galectin Therapeutics to present at the Paris NASH meeting on the use of AI in studying liver cirrhosis. They will share data from their previous phase 2 cirrhosis program and discuss their pivotal program on portal hypertension. They have collected over 500 video recordings of esophago-gastro-duodeno endoscopies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.32%
Tags
conferences
Galectin Therapeutics Inc

Nasdaq:GALT

GALT Rankings

GALT Stock Data

147.82M
42.64M
31.07%
11.69%
3.46%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Berkeley Lake

About GALT

galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much